Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants

Pancreatic ductal adenocarcinoma (PDAC) still presents a grim prognosis with less than 10% of newly diagnosed patients alive after 5-year, and by the end of 2030 PDAC is expected to become the second leading cause of cancer-related death in the United States [12]. Currently, only 15 –20% of patients are diagnosed with resectable disease and even with radical surgery 75% of them will recur within 5 years, supporting the idea of PDAC as a systemic disease since the onset. In metastatic or unresectable cancers, FOLFIRINOX and nab-paclitaxel plus gemcitabine regimens represent th e standard treatment, however offering a disappointing outcome in terms of overall survival (OS) and supporting the urgent need of novel therapies and approaches for selected patients [34].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research